Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Dig Dis. 2022;40(6):745-753. doi: 10.1159/000521768. Epub 2022 Jan 5.

Abstract

Introduction: Chronic hepatitis B (CHB) patients with metabolic syndrome (MetS) may present increased risk of liver-related outcomes (LROs), but prior studies were limited by small sample size and/or conflicting results. Using a systematic review and meta-analytic approach, we aimed to determine the association between MetS and LROs in CHB.

Methods: Two researchers independently screened studies from the PubMed, Embase, Web of Science, and Cochrane Library databases from inception to January 21, 2020, and extracted the data. Estimates were pooled using a random-effects model.

Results: We screened 2,228 articles and included 10 eligible studies (18,360 CHB patients, 2,557 with MetS). MetS was significantly associated with LROs overall (odds ratio = 2.45, 95% confidence interval = 1.39-4.32) but not the individual LRO components but subgroup analyses were limited by small study numbers.

Discussion/conclusion: MetS is associated with almost 3-folds higher risk of LROs in CHB and should be considered in management decisions. However, additional studies are needed.

Keywords: Diabetes; Hepatocellular carcinoma; Liver fibrosis; Mortality; Prognosis.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Hepatitis B, Chronic* / complications
  • Humans
  • Metabolic Syndrome* / complications
  • Metabolic Syndrome* / epidemiology
  • Odds Ratio

Grants and funding

There are no funding sources to declare.